Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review.
about
Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.High-risk childhood acute lymphoblastic leukemiaA critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.The management of high-risk lymphoblastic leukaemia in children.Recent advances in management of acute leukaemia.Hematopoietic stem cell transplantation for leukemiaEarly Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in YogyakartaClinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual diseaseAugmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic lPrediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemiaSurvival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UKClinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia.Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment.The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries.Treatment outcome of young children with acute lymphoblastic leukaemia: achievements and directions implied from Shanghai Children's Medical Centre based SCMC-ALL-2005 protocol.Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia.Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors?Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction.Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group.Early response to therapy and survival in multiple myeloma.Clinical outcome of children with newly diagnosed acute lymphoblastic leukemia treated in a single center in Shanghai, China.Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG).
P2860
Q33388076-D67AE16F-26D1-4F98-A271-30C946E2AC1FQ33622837-D9335C53-0247-45C0-91AB-5AA065030D5EQ33735167-F5F34CBA-BF35-4659-80A7-5D14378ECDADQ33744912-7971F277-8D03-4325-A351-DC089FA0A9CCQ33848509-CDE95586-F149-41A3-8564-FE590EF77624Q33930802-DCE9732A-0BC0-4721-A173-7E1C9DBD1021Q34034180-5D350B3D-2671-4791-A758-9A3DDFEEDE4EQ34252624-A8C83385-C267-4790-A572-D09A0A9C121AQ34488796-7597596D-AFB0-43C7-95F0-2D695A56A739Q35022780-145B4447-9F79-4F1A-8145-548CD3F11CA7Q35106033-F2ACA45A-7B4C-4574-98CA-C833E33A0D38Q35571035-4120DF54-4917-4F44-98D2-B9CA6428C11AQ35616078-0B57202E-F4A9-4E52-B85E-E734EEE9E81CQ35849907-C5B308AC-1C77-47E8-A6D7-C463CE7B1E90Q35853569-E9885CE5-9F55-4DEA-BCE8-6A282FC3823FQ35925012-7FBBBF86-BC71-4A5A-BF82-926E0D8A95F2Q36094717-DDC3E528-268E-470C-AD3B-73E5CD9BC5A2Q36610199-3E903A21-192F-49CA-95CB-A9D394971B9CQ36713493-AE73390F-86DD-43E1-A993-7D0C05FA4A9FQ37126934-2B442E6C-90C7-472B-B524-97C920E3FAF0Q37284741-E77A855F-BBEE-49F2-88A9-34F21C2E0FB7Q37416851-C2F55F18-015C-4326-BD01-1D2BB797274FQ38055164-D86704D5-D864-45DA-8A61-C339E588CB85Q38458733-2CAAE395-EDA0-4F28-B351-2BDB4AF08681Q39510856-21356538-E097-49D7-A586-BF3B39463868Q41500605-8B48A907-FDD9-4B31-9B27-1586CD74A9FAQ43120483-05ECC04A-ACF8-4D3F-A41C-4BBE7A4E5A92Q43487784-8F4533DB-F5A1-471D-AF3F-CB4EE28B3B8DQ43591842-59A9DD12-6515-440B-9922-6D014D44DB16Q43805387-57E07E05-9A1C-470B-A3F1-49399386F86CQ44319724-15CF8179-CB37-4386-AE82-A98817AF8BDDQ44364245-3CB3C1ED-FC23-4513-9CBC-3586966E2A84Q44826301-EF6700CA-EE47-4955-BDB8-8DB8A8EAB81CQ46735733-10BE8800-544A-410E-B50C-33607DC52031Q50209854-F1E59590-A2A1-40AC-B4FD-54D2168F1B47Q54773234-98183CB7-90BE-420A-A7EA-CBDF45DC526B
P2860
Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Early response to therapy and ...... phoblastic leukemia: a review.
@en
type
label
Early response to therapy and ...... phoblastic leukemia: a review.
@en
prefLabel
Early response to therapy and ...... phoblastic leukemia: a review.
@en
P2093
P2860
P1433
P1476
Early response to therapy and ...... phoblastic leukemia: a review.
@en
P2093
Bostrom BC
Hutchinson RJ
Nachman JB
Steinherz PG
P2860
P304
P356
10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B
P407
P577
1997-11-01T00:00:00Z